



2654 5 JUL 25 A9:44

July 15, 2005

Dr. Stephen Galson:  
Dockets Management Branch  
US Food and Drug Administration  
Department of Health and Human Resources  
Room 1-23  
12420 Parklawn Drive  
Rockville, MD 20857

**Re: Docket Number 2005-00107  
Citizens Petition concerning glycoprotein IIb/IIIa inhibitors – tirofiban,  
lamifiban, eptifibitide, and abciximab for acute coronary syndromes in women**

Dear Dr. Galson:

In accordance with CFR 10.30, Guilford Pharmaceuticals Inc. is submitting four copies of the attached document in response to Citizen Petition No. 2005-00107 "Citizens Petition concerning glycoprotein IIb/IIIa inhibitors – tirofiban, lamifiban, eptifibitide, and abciximab for acute coronary syndromes in women," dated March 1, 2005. Guilford's stance on the petition is detailed and is attached. Literature references are also included. Agency dialogue is welcomed regarding this position.

If you require further information, please contact me at (410) 631-8556, or in my absence, Ms. Nataskia Lampe, at (410) 631-8156.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Timothy K. Ressler".

Timothy K. Ressler  
Vice President, Regulatory Affairs

TKR/ikb

cc: Norman Stockbridge, M.D., Ph.D.  
Acting Director  
Division of Cardio-Renal Drug Products  
Office of Drug Evaluation and Research

2005P-0107

C1

July 15, 2005

To Whom It May Concern,

We appreciate Dr. Redburg's concern regarding the use of GP IIb/IIIa receptor antagonists in women with ACS based on the meta-analysis published by Boersma, et al<sup>1</sup>. Given the impact that coronary artery disease has on women's health, it is important to discern gender differences in treating this disease whenever possible. However, we do not agree with Dr. Redburg's conclusion that all GP IIb/IIIa inhibitors should undergo a labeling change based on Boersma's meta-analysis data.

Claiming a class effect based upon Boersma's data is problematic for reasons outlined below. It is widely believed that a meta-analysis cannot take the place of properly designed and well-controlled clinical trials. Drawing valid conclusions about subgroups of patients from the meta-analysis is even more difficult—particularly when it appears there are subgroups of women (see below) who may benefit from the treatment in question.

The studies included in the meta-analysis make an argument for a GP IIb/IIIa inhibitor class effect for women untenable, as many of these studies evaluated drug regimens that are not approved for ACS patients. PARAGON A and PARAGON B were two studies involving lamifiban. Lamifiban was never approved by the FDA for treating ACS patients, regardless of sex. Similarly, the GUSTO IV trial demonstrated worse outcomes for ACS patients receiving abciximab in whom an early invasive management strategy was not planned. Based on these results, abciximab is contra-indicated in this ACS patient population/setting. Finally, the PRISM trial, a comparison of tirofiban to heparin on a background of aspirin, is not in keeping with the approved indication for tirofiban, which includes the use of heparin and aspirin concomitantly. In the PRISM-PLUS trial, the tirofiban alone arm was terminated early due to a finding of increased mortality.

An analysis of women in the PRISM-PLUS trial was published, evaluating the use of tirofiban plus heparin versus heparin alone<sup>2</sup>. Early timepoints demonstrated a trend toward a benefit for female ACS patients who were treated with tirofiban/heparin. While later timepoints (30 and 180 days) did not demonstrate a sustained benefit, they also did not demonstrate an increased risk for adverse outcomes, as was reported in the meta-analysis and specific GP IIb/IIIa inhibitor trials within the meta-analysis (e.g., PURSUIT). Investigators acknowledged that small patient numbers make interpretation of the PRISM-PLUS data difficult. Furthermore, cardiac biomarkers (troponin levels) were not captured in PRISM-PLUS, making it difficult to determine how the subset of troponin positive women fared.

In the Boersma meta-analysis the subset of women who had positive troponin levels appeared to benefit from GP IIb/IIIa inhibitors as did the troponin positive men, even though information on baseline cardiac troponins was only available for 35% of the entire population. "There was no statistical evidence of a differential treatment effect between men and women if patients were stratified according to their baseline troponin concentration<sup>1</sup>." This finding caused the investigators to question whether both sexes were similar with regard to the significance and instability of the underlying CAD. The investigators felt that the difference in results based on gender may be more a reflection of the underlying pathobiology of the ACS, with the group of patients who experienced plaque rupture and intracoronary thrombus formation responding favorably to intensive antiplatelet therapy regardless of sex. Given this belief, they concluded that ... "a differential treatment strategy between men and women presenting with definite ACS is not recommended at present<sup>1</sup>." This conclusion is in keeping with clinical practice and the ACC/AHA guidelines<sup>3</sup>, which recommend the use of GP IIb/IIIa inhibitors for patients undergoing PCI and for high-risk ACS patients in whom PCI/cath is not planned

We share Dr. Redburg's desire to find the optimal pharmacotherapy to treat women with ACS. While some GP IIb/IIIa inhibitors may be ineffective/harmful for certain subgroups of patients, it is misleading to extrapolate individual study results to a class of medications when the studies examined do not reflect labeled indications or current clinical practice. While the lack of prospective randomized clinical trial data for women with ACS is frustrating, we do not believe it prudent to rely on imperfect methods of data analysis for subgroups as a substitute to a well-designed clinical trial — particularly when there may be high-risk subgroups of women who may benefit from the treatment.

#### References:

1. Boersma E, Robert A. Harrington, David J. Moliterno, Harvey White, Pierre Theroux, Frans Van de Werf, Anneke de Torbal, Paul W. Armstrong, Lars C. Wallentin, Robert G. Wilcox, John Simes, Robert M. Califf, Eric J. Topol, and Maarten L. Simoons. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials, *Lancet* 2002; 359:189-98.
2. Huynh, T et al. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). *Am Heart J* 2003; 46:668-73.
3. Braunwald, E et al. ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--Summary Article. *J Am Coll Cardio* 2002; 40:1366-74.

# Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study)

Thao Huynh, MD,<sup>a</sup> Pierre Theroux, MD,<sup>b</sup> Steven Snapinn, PhD,<sup>c</sup> and Ying Wan, MSc,<sup>c</sup> for the PRISM-PLUS Investigators Montreal, Quebec, Canada, and Blue Bell, Pa

**Background** Previous trials demonstrated the efficacy of platelet glycoprotein IIb/IIIa receptors blockade with tirofiban in reducing acute ischemic events in patients with unstable angina/non-ST-elevation myocardial infarction. Little is known about the effect of tirofiban among women with acute coronary syndromes.

**Objective** We aimed to determine the benefit and safety of tirofiban plus heparin versus heparin alone on cardiac ischemic events among women with unstable angina/non-ST-elevation myocardial infarction.

**Method and Results** We performed a post hoc analysis of all women enrolled in the PRISM-PLUS trial. At early time points, there appeared to be a reduction of the primary composite end point of death, myocardial infarction, or refractory ischemia among women treated with tirofiban plus heparin (RR, 0.78 and 0.67) compared with women treated with heparin alone. However, at 30 and 180 days, there was no significant reduction of events with the combination therapy of tirofiban plus heparin (treatment-by-sex interaction,  $P = .05$ ). Death or myocardial infarction was not significantly reduced by the combination therapy among women at all time points.

**Conclusions** Although the effects of tirofiban in reducing the primary composite outcome were similar among men and women early in the study, there appeared to be a difference at the later time points. In particular, tirofiban was effective among men, but there was no clear effect among women at 30 and 180 days. (*Am Heart J* 2003;146:668–73.)

Platelet activation and aggregation are pivotal in the pathophysiology of acute coronary syndromes. Numerous clinical trials have demonstrated the effectiveness of platelet glycoprotein IIb/IIIa inhibitors in reducing life-threatening complications in patients with acute coronary syndromes.<sup>1–4</sup> Tirofiban had been shown to be effective in reducing death, myocardial infarction, or refractory ischemia in patients with unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI).<sup>1,2</sup> However, little is known about the benefit and safety of tirofiban among women with coronary syndromes. The objective of this study was to examine, in a post hoc analysis of the PRISM-PLUS data,

whether the addition of tirofiban to standard anti-thrombotic therapy would be effective in women.

## Methods

The study population, design, and the main findings of the PRISM-PLUS study have been described in detail elsewhere.<sup>2</sup> The initial study design involved double-blind random assignment to 1 of 3 treatment groups: tirofiban alone, tirofiban plus heparin, or heparin alone. At an interim analysis, the tirofiban-alone arm of the study was prematurely discontinued on the recommendation of the Data Safety Monitoring Board, secondary to an excessive 7-day mortality rate in these patients.

## Study end points

The primary end point of PRISM-PLUS was a composite of death from any cause, new myocardial infarction (MI), or refractory ischemia within 7 days after random assignment. Rehospitalization for UA/NSTEMI was also counted in the composite primary end point when assessed at 7 days, 30 days, and 6 months. Predefined secondary end points included the same composite end point 48 hours and 30 days after random assignment, the 3 components of this end point as separate measures, and a composite of death or MI.

From <sup>a</sup>Montreal General Hospital, Montreal, Quebec, <sup>b</sup>Montreal Heart Institute, Montreal, Quebec, Canada, and <sup>c</sup>Merck Research Laboratories, Blue Bell, Pa. The PRISM-PLUS trial was sponsored by Merck Research Laboratories. Dr Snapinn and Ms Wan are employees of Merck Research Laboratories. Submitted August 19, 2002; accepted January 15, 2003. Reprint requests: Thao Huynh, MD, Montreal General Hospital, 1650 Cedar Ave, Room E-5200, Montreal, Quebec H3G-1A4, Canada. E-mail: thao.huynh@mhuc.mcgill.ca © 2003, Mosby, Inc. All rights reserved. 0002-8703/2003/\$30.00 + 0 doi:10.1016/S0002-8703(03)00255-2

MI was defined as a new episode of chest pain of at least 20 minutes in duration with new Q waves or a rise in the serum creatine kinase level to 2 times the upper limit of normal. Refractory angina included the following symptoms: chest pain  $\geq 20$  minutes in duration, repetitive chest pains with transient ST-T changes, or recurrent ischemia with pulmonary edema or hypotension or requiring intra-aortic counterpulsation or urgent coronary intervention. All events were evaluated by an end point committee blinded to treatment assignment.

### Assessment of safety

Bleeding events were assessed throughout the duration of study drug infusion and for 24 hours after infusion by using the criteria developed by the Thrombolysis in Myocardial Infarction trial group. Major bleeding was defined as a decrease in the hemoglobin levels of  $\geq 40$  g/L, the need for transfusion of  $> 2$  units of blood, the need for corrective surgery, the occurrence of an intracranial or retroperitoneal hemorrhage or cardiac tamponade, or any combination of these events. Minor bleeding was defined as a decrease of  $\geq 30$ g/L.<sup>5</sup>

### Statistical analysis

The present report focused only on the comparison between the patients treated with tirofiban plus heparin and heparin alone. We excluded the patients who were randomly assigned to the tirofiban-alone therapy from analysis because this arm was discontinued prematurely. The Pearson  $\chi^2$  test was used to compare the baseline characteristics and bleeding complications except for the mean age, which was compared by Student *t* test. Clinical events were analyzed by means of a Cox proportional hazards model, and the risk ratios presented are based on these models. Tests for the effect of tirofiban were based on a model with an indicator for treatment; tests for treatment by sex additionally included an indicator for sex and the product of the treatment and sex indicators. All Cox regression models included adjustments for prior use of heparin and antecedent use of aspirin. All probability values were 2-sided, with values  $\leq .05$  considered significant.

### Results

A total of 1915 patients were enrolled in the main study. We excluded 345 patients enrolled in the tirofiban-alone arm. Of the remaining 1570 patients, there were 252 women (31.6%) in the group who received tirofiban plus heparin and 254 women (32.9%) in the heparin arm.

Table I describes the demographic characteristics of women and men. The mean age was comparable between the two sexes. Although women had more hypertension ( $P < .0001$ ) and diabetes mellitus ( $P = .04$ ), they had less prior MI and coronary bypass surgery than men ( $P < .0001$ ). High-risk clinical features such as transient ST elevation and NSTEMI were found more often in men ( $P = .03$ ), whereas women had more T-wave inversion ( $P = .03$ ). However, the mean TIMI risk score<sup>6</sup> was similar in both sexes (3.87 for

**Table I.** Baseline characteristics of patients by sex

Characteristics	Men (n = 1064)	Women (n = 506)	P
Mean age (y $\pm$ SD)	61.9 $\pm$ 11.62	65.8 $\pm$ 11.30	.46
Prior myocardial infarction (%)	498 (46.8)	155 (30.6)	<.001
Prior congestive heart failure (%)	100 (9.4)	50 (9.9)	.76
Prior percutaneous coronary intervention (%)	107 (10.6)	39 (7.7)	.13
Prior coronary artery bypass surgery (%)	187 (17.6)	44 (8.7)	<.001
Smoking (%)	862 (81.3)	245 (48.5)	<.001
Hypertension (%)	525 (49.3)	348 (68.8)	<.001
Hypercholesterolemia (%)	524 (49.3)	257 (50.8)	.57
Diabetes mellitus (%)	229 (21.5)	133 (26.3)	.036
Unstable angina (%)	558 (52.4)	298 (58.9)	.02
Non ST-elevation myocardial infarction (%)	506 (47.6)	208 (41.1)	
Transient ST elevation (%)	162 (15.2)	56 (11.1)	.026
ST depression (%)	614 (57.7)	305 (60.3)	.33
T waves inversions (%)	534 (50.2)	283 (55.9)	.033
Prior therapy: aspirin (%)	547 (51.4)	267 (52.8)	.62
Prior heparin (%)	700 (65.8)	307 (60.7)	.048

men and 3.88 for women). The baseline characteristics were similar among the women randomly assigned to the two treatment arms.

The incidences of the primary end point and the secondary combined end point of MI and death in women versus men, irrespective of treatment, are presented in Table II. Despite considerable differences in baseline characteristics, women and men had similar rates of adverse outcomes, which is consistent with their similar TIMI risk scores.


Figure 1 presents the risk ratios for the effect of tirofiban on the primary end point and the combined end point of death and MI among women and men. Tirofiban was clearly beneficial in men, with a reduction of both the composite primary end point and the combined end point of death and MI, at all time points. Men treated with tirofiban plus heparin had a risk ratio of 0.67, 0.68, 0.73, and 0.71 for the composite end point at 48 hours and 7, 30, and 180 days.

Table III compares the outcomes among women who received tirofiban plus heparin compared with the women who were receiving heparin alone. At early time points, women appeared to have similar reduction of the composite end point with tirofiban as men. The risk ratios for the composite end point were 0.78 and 0.67 at 2 and 7 days, respectively, for women who received heparin plus tirofiban. However, there was no clear effect of tirofiban on death and MI among women at all time points. A statistical test for quantitative interaction between tirofiban and sex was significant, with  $P = .05$  for the 180-day composite

**Table II.** Outcomes at 2, 7, 30, and 180 day by sex

Time	Events	Women, n = 506 (%)	Men, n = 1064 (%)	Risk ratios (95% CI)	P
48 Hours	Composite	34 (6.7)	72 (6.8)	1.02 (0.68–1.53)	.94
	MI/Death	7 (1.4)	21 (2.0)	0.71 (0.30–1.66)	.42
7 Days	Composite	82 (16.2)	161 (15.1)	1.09 (0.83–1.42)	.55
	MI/Death	30 (5.9)	74 (7.0)	0.84 (0.55–1.29)	.43
30 Days	Composite	105 (20.8)	216 (20.3)	1.04 (0.83–1.32)	.73
	MI/Death	51 (10.1)	111 (10.4)	0.95 (0.69–1.33)	.78
180 Days	Composite	164 (32.4)	306 (28.8)	1.16 (0.96–1.40)	.13
	MI/Death	68 (13.4)	149 (14.0)	0.95 (0.71–1.26)	.70

Composite, Death or myocardial infarction or refractory ischemia; MI, myocardial infarction

**Figure 1**

Effects of treatment (T+H vs H) on end points at various time points in women and men. T+H, Tirofiban plus heparin; H, heparin; MI, myocardial infarction.

primary end point, indicating that the effect of tirofiban among men was significantly greater than its effect among women.

### Bleeding complications

Table IV presents the overall bleeding complications among men and women, irrespective of treatment. Major bleeds were rare in both sexes. Women had more minor bleeds than men. The incidences of bleeding complications among men and women, by treatment allocation, are shown in Table V. Although there appeared to be an increase in bleeding complications in women treated with tirofiban and heparin, this did not reach statistical significance.

### Discussion

Women with UA/NSTEMI who were enrolled in PRISM-PLUS had similar rates of reduction in the com-

posite end point of death, MI, and refractory ischemia with tirofiban as men at 2 and 7 days. However, contrary to men, there was no clear benefit of tirofiban seen at 30 and 180 days among women treated with tirofiban plus heparin. There was also no significant reduction of death and myocardial infarction in women by tirofiban at all time points. Was this sex differential response to tirofiban the result of true biological difference or of chance? Can this be explained by different pathophysiological mechanisms of acute coronary syndromes or biological response to the glycoprotein IIb/IIIa receptor inhibitors?

### Sex differences in platelet reactivity

Previous studies suggested sex differences in platelet reactivity, with a greater sensitivity of the platelets of women to aggregating stimuli.<sup>7,8</sup> Faraday et al<sup>8</sup> demonstrated a 50% to 80% increase of activated glycoprotein IIb/IIIa receptors in women compared with men given the same agonist. Given their increased platelet reactivity, it is possible that women may have different responses to glycoprotein receptors IIb/IIIa blockade.

### Effects of glycoprotein IIb/IIIa antagonism in women undergoing percutaneous coronary intervention

Cho et al<sup>9</sup> and Fernandes et al<sup>10</sup> showed the benefits of abciximab and eptifibatid, respectively, in reduction of adverse outcomes among women who underwent percutaneous coronary intervention. They did not find any sex-related response to treatment. However, these studies focused exclusively on patients who had percutaneous coronary intervention. The effect of glycoprotein IIb/IIIa receptor inhibitors in women with acute coronary syndromes is less well studied.

Although the benefit of eptifibatid was not seen in the whole group of women enrolled in PURSUIT,<sup>4</sup> eptifibatid was beneficial in reducing acute ischemic events in American women.<sup>11</sup> This may reflect the high revascularization rate in the United States<sup>4,11</sup> and

**Table III.** Treatment effects in women

Events		Tirofiban + heparin (%)	Heparin (%)	Risk ratios (95% CI)	P	Sex treatment interaction P
48 Hours	Composite	15 (5.9)	19 (7.5)	0.78 (0.40–1.53)	.47	.72
	MI/Death	3 (1.2)	4 (1.6)	0.73 (0.16–3.3)	.69	.23
7 Days	Composite	34 (13.4)	48 (19.0)	0.67 (0.43–1.04)	.08	.98
	MI/Death	14 (5.5)	16 (6.3)	0.86 (0.42–1.78)	.69	.18
30 Days	Composite	51 (20.1)	54 (21.4)	0.89 (0.61–1.31)	.56	.37
	MI/Death	26 (10.2)	25 (9.9)	1.02 (0.59–1.77)	.94	.099
180 Days	Composite	85 (33.5)	79 (31.3)	1.02 (0.76–1.40)	.86	.05
	MI/Death	36 (14.2)	32 (12.7)	1.11 (0.69–1.78)	.68	.08

**Table IV.** Bleeding complications among men and women

	Women, n = 506 (%)	Men, n = 1064 (%)	Risk ratios (95% CI)	P
TIMI major bleeding	8 (1.6)	9 (0.8)	1.87 (0.73–4.82)	.19
TIMI minor bleeding	64 (12.7)	81 (7.6)	1.66 (1.22–2.27)	.001
All TIMI bleeding	77 (15.2)	97 (9.1)	1.67 (1.26–2.21)	.0003

TIMI, Thrombolysis in Myocardial Infarction trial.

**Table V.** Incidence of bleeding complications among men and women by treatment

	Heparin + tirofiban (%)	Heparin (%)	Risk ratios (95% CI)	P	Treatment-sex interaction P
Women	254	252			
TIMI major bleeding	6 (2.4)	2 (0.8)	2.98 (0.61–14.61)	.16	.43
TIMI minor bleeding	37 (14.6)	27 (10.7)	1.36 (0.85–2.16)	.19	.76
All TIMI bleeding	44 (17.3)	33 (13.1)	1.32 (0.87–2.01)	.19	.83
Men	519	545			
TIMI major bleeding	5 (1.0)	4 (0.7)	1.31 (0.35–4.86)	.68	.68
TIMI minor bleeding	44 (8.5)	37 (6.8)	1.25 (0.82–1.90)	.30	.30
All TIMI bleeding	53 (10.2)	44 (8.1)	1.26 (0.86–1.85)	.23	.23

the well-proven benefit of glycoprotein IIb/IIIa receptor blockade in patients who underwent coronary revascularization.<sup>11–17</sup>

### Glycoprotein IIb/IIIa blockade in women with acute coronary syndromes

Are women with acute coronary syndromes a lower-risk group, and thus the benefit of potent antiplatelet drugs is less evident? Hochman et al<sup>18</sup> demonstrated that among patients with unstable angina, female sex was associated with an independent protective effect for death or MI (OR, 0.65; CI, 0.49 to 0.87). Among the patients enrolled in PURSUIT, Boersma et al<sup>19</sup> showed that women were at lower risk than men for 30-day death/MI (OR, 0.56; CI, 0.45 to 0.89).

Boersma et al<sup>20</sup> performed a meta-analysis of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes that included the PRISM-PLUS data presented in this article. They observed a differential treatment effect between men and women. In women, the odds ratio and confidence interval were consistent with a possible risk increase with glycoprotein IIb/IIIa receptor inhibitors (11.5% versus 10.4%, 30-day events; OR, 1.15; CI, 1.02 to 1.30). However, the difference in therapeutic response between men and women was no longer present when patients were stratified according to their baseline troponin level. A reduction of 30-day death/MI was seen in both men and women with elevated troponin level, whereas no benefit was observed in patients with normal troponin level, irre-

spective of sex. Serum troponin elevation appeared to be a reliable tool to identify women at risk for acute ischemic events, who will benefit from glycoprotein IIb/IIIa receptors inhibitors.

Compared with the above meta-analysis,<sup>20</sup> we had more long-term data with 6-month outcomes, in-hospital refractory ischemia, and rehospitalization for acute coronary syndromes. Our patients were a more homogenous group, with only one glycoprotein IIb/IIIa receptor inhibitor being studied.

The lack of an obvious benefit of tirofiban of death, MI, and refractory ischemia among women at 30 and 180 days in PRISM-PLUS could be explained by the small sample size. There was also no effect of tirofiban on death and MI among women at all time points. The significant sex and treatment interaction at 180 days ( $P = .05$ ) raised the possibility of a true different sex response with tirofiban and that tirofiban was less protective in reducing late ischemic events in women. The explanation for this finding remained unclear.

Could it be that the women enrolled in PRISM-PLUS were lower-risk patients, so that the long-term benefit of tirofiban was not shown? This did not appear to be the case. These women appeared to be as high-risk as the male patients, with similar TIMI scores (3.87 for men and 3.88 for women) and rates of cardiac adverse outcomes. The rates of revascularization were also similar between the two sexes (55.1% for men and 52.4% for women).

#### Angiographic data among women with acute coronary syndromes

Angiographic data from many clinical trials and registries<sup>21-25</sup> showed less clinically significant coronary artery disease and multivessel coronary artery disease in women than in men. This did not necessarily imply that the diagnosis of an acute ischemic event was incorrect in these patients. Twenty-five percent of women with insignificant coronary stenosis in PURSUIT had confirmed MI. Myocardial infarction was confirmed by enzymatic criteria in 41.1% of the women enrolled in PRISM-PLUS.<sup>2</sup> Thrombus formation may play a less important role in the pathophysiology of acute coronary syndromes in women, and the underlying coronary disease in these patients may be less severe.

Zhao et al<sup>25</sup> reported the angiographic results of patients enrolled in PRISM-PLUS. Female sex was predictive, by univariate analysis, of less coronary artery thrombus. However, it was no longer a significant predictor by multivariate analysis. This finding implied that although female sex by itself was not an independent predictor, there was less active coronary thrombus in women. A potential explanation for our results may be that our female patients had less intracoronary

thrombus and/or less severe underlying coronary disease and thus derived less benefit from tirofiban.

#### Bleeding events among women

Women enrolled in this study had significantly more minor bleeds than men, irrespective of treatment group. We did not observe a significant increase of bleeding complications in women treated with tirofiban and heparin; however, this can be due to lack of power secondary to the small sample size.

#### Limitations

First, our study had the inherent limitations of a post hoc subgroup analysis.<sup>26</sup> The sample size was likely too small to show a significant benefit of tirofiban in women; however, our results were in concordance with Boersma meta-analysis of glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndromes.<sup>20</sup> Sex-treatment interaction confirming the differential therapeutic response between men and women was significant at 180 days. These findings raised the possibility of a true differential sex response to tirofiban.

Second, PRISM-PLUS enrollment took place during 1994 to 1996, before widespread implementation of serum troponin measurement. Since serum troponin was not available, we could not validate the previous report that elevation of serum troponin was a more important predictor of response to glycoprotein receptor IIb/IIIa blockade than sex.<sup>20</sup>

Third, although the majority of patients did undergo diagnostic coronary angiography (78.3%), coronary anatomy was not available in 112 women (22.2% of the women enrolled).<sup>25</sup> We could not validate the hypothesis that tirofiban may be less beneficial in women because of less severe coronary artery disease in these patients. Finally, although we did not observe a significant increase in bleeding complications among women assigned to heparin plus tirofiban, this can be due to the lack of power of the small sample size.

#### Conclusions

At early time points, women with UA/NSTEMI who were enrolled in PRISM-PLUS had similar rates of reduction of the primary composite outcome as men with tirofiban. However, at 30 and 180 days, there was no significant reduction of events with the combination therapy. Death or MI was not significantly reduced by the combination therapy of tirofiban plus heparin at all time points.

Although the explanation was unclear, it may be that women had less severe underlying coronary artery disease with less active thrombus. Serum troponin elevation may be helpful in identifying high-risk women who will benefit more from glycoprotein IIb/IIIa receptor inhibitors. Future studies focusing on platelet

glycoprotein IIb/IIIa receptor inhibitors and serum troponin elevation in women with acute coronary syndromes are needed.

*We thank Dr Peter Dibattiste for his invaluable input, guidance, and help in the completion of the manuscript.*

## References

1. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. *N Engl J Med* 1998;338:1498-505.
2. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. *N Engl J Med* 1998;338:1488-97.
3. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor) or heparin, or both in unstable angina: platelet IIb/IIIa Antagonism for the Reduction of Acute coronary events in a Global Organization Network. *Circulation* 1998;97:2386-95.
4. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatid in patients with acute coronary syndromes. *N Engl J Med* 1998;339:436-43.
5. Cheesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. *Circulation* 1987;76:142-54.
6. Antman E, Cohen M, Bernink P, et al. The TIMI risk score for unstable angina/non-ST-elevation myocardial infarction. *JAMA* 2000;284:835-42.
7. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. *Nature* 1975;253:353-7.
8. Faraday N, Goldschmidt-Clermont PJ, Bray P. Gender differences in platelet GPIIb/IIIa activation. *Thromb Haemost* 1997;77:748-54.
9. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. *J Am Coll Cardiol* 2000;35:381-6.
10. Fernandes LS, Tchong JE, O'Shea JC, et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study. *J Am Coll Cardiol* 2002;40:1085-91.
11. Lincoff AM, Harrington RA, Califf RM, et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition: insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrin therapy (PURSUIT) Trial. *Circulation* 2000;102:1093-100.
12. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE trial. *Lancet* 1997;349:1429-35.
13. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary intervention. *J Am Coll Cardiol* 1997;30:149-56.
14. Kleiman NS, Lincoff ML, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatid, and clinical outcomes in patients with acute coronary syndromes. *Circulation* 2000;101:751-7.
15. IMPACT-II Investigators. Randomized placebo-controlled trial of effect of eptifibatid on complications of percutaneous coronary intervention: IMPACT-II. *Lancet* 1997;3349:1422-8.
16. ESPRIT investigators. Novel dosing regimen of eptifibatid in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. *Lancet* 2000;356:2037-44.
17. Boersma E, Akkerhuis M, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. *Circulation* 1999;100:2045-8.
18. Hochman JS, Tams JE, Thompson TD. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. *N Engl J Med* 1999;341:226-32.
19. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. *Circulation* 2000;101:2557-67.
20. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. *Lancet* 2002;359:189-98.
21. GUSTO-IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. *N Engl J Med* 1996;335:775-82.
22. Roe MT, Harrington RA, Prosper DM, et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. *Circulation* 2000;102:1101-6.
23. Hochman JS, McCabe CH, Stone PH, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIb. *J Am Coll Cardiol* 1997;30:1141-8.
24. Scirica BM, Moliterno DJ, Every NR, et al. Differences between men and women in the management of unstable angina pectoris (the GUARANTEE Registry). *Am J Cardiol* 1999;84:1145-50.
25. Zhao XQ, Theroux P, Snapinn SM, et al. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-Wave myocardial infarction. *Circulation* 1999;100:1609-15.
26. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. *JAMA* 1991;266:93-8.

## ACC/AHA PRACTICE GUIDELINES

# ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction—Summary Article

A Report of the American College of Cardiology/  
American Heart Association Task Force on Practice Guidelines  
(Committee on the Management of Patients With Unstable Angina)

### COMMITTEE MEMBERS

EUGENE BRAUNWALD, MD, FACC, FAHA, *Chair*

ELLIOTT M. ANTMAN, MD, FACC, FAHA  
JOHN W. BEASLEY, MD, FAFAP  
ROBERT M. CALIFF, MD, FACC  
MELVIN D. CHEITLIN, MD, FACC  
JUDITH S. HOCHMAN, MD, FACC, FAHA  
ROBERT H. JONES, MD, FACC  
DEAN KERELAKES, MD, FACC

JOEL KUPERSMITH, MD, FACC, FAHA  
THOMAS N. LEVIN, MD, FACC  
CARL J. PEPINE, MD, MACC, FAHA  
JOHN W. SCHAEFFER, MD, FACC, FAHA  
EARL E. SMITH III, MD, FACEP  
DAVID E. STEWARD, MD, FACP  
PIERRE THEROUX, MD, FACC, FAHA

### TASK FORCE MEMBERS

RAYMOND J. GIBBONS, MD, FACC, FAHA, *Chair*

ELLIOTT M. ANTMAN, MD, FACC, FAHA, *Vice Chair*

JOSEPH S. ALPERT, MD, FACC, FAHA  
DAVID P. FAXON, MD, FACC, FAHA  
VALENTIN FUSTER, MD, PhD, FACC, FAHA  
GABRIEL GREGORATOS, MD, FACC, FAHA

LOREN F. HIRATZKA, MD, FACC, FAHA  
ALICE K. JACOBS, MD, FACC, FAHA  
SIDNEY C. SMITH, Jr, MD, FACC, FAHA

## INTRODUCTION

The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for the management of unstable angina and non-ST-segment elevation myocar-

dial infarction (UA/NSTEMI) were published in September 2000 (1). Since then, a number of clinical trials and observational studies have been published or presented that, when taken together, alter significantly the recommendations made in that document. Therefore, the ACC/AHA

The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur.

This document was approved by the American College of Cardiology Foundation Board of Trustees in September 2002 and by the American Heart Association Science Advisory and Coordinating Committee in August 2002.

When citing this document, the American College of Cardiology Foundation and the American Heart Association would appreciate the following citation format: Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kerelakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P. ACC/AHA 2002 guideline update for the

management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). *J Am Coll Cardiol* 2002;40:1366-74.

This document is available on the World Wide Web sites of the ACC ([www.acc.org](http://www.acc.org)) and the AHA ([www.americanheart.org](http://www.americanheart.org)). Single copies of this document are available for \$5 each by calling 800-253-4636 (US only) or writing the American College of Cardiology Foundation, Resource Center, 9111 Old Georgetown Road, Bethesda, MD 20814-1699 (product code 71-0227). This document and the companion full-text guidelines (product code 71-0240), are available on the ACC Web site at [www.acc.org](http://www.acc.org) and the AHA Web site at [www.americanheart.org](http://www.americanheart.org). To purchase additional reprints (specify version): up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1,000 or more copies, call 214-706-1466, fax 214-691-6342; or E-mail [pubauth@heart.org](mailto:pubauth@heart.org).

Committee on the Management of Patients With Unstable Angina, with the concurrence of the ACC/AHA Task Force on Practice Guidelines, revised these guidelines. These revisions were prepared in December 2001, reviewed and approved, and then published on the ACC World Wide Web site ([www.acc.org](http://www.acc.org)) and AHA World Wide Web site ([www.americanheart.org](http://www.americanheart.org)) on March 15, 2002. The present article describes these revisions and provides further updates in this rapidly moving field. Minor clarifications in the wording of three recommendations that now appear differently from those that were previously published on the ACC and AHA Web sites are noted in footnotes.

The ACC/AHA classifications I, II, and III are used to summarize indications as follows:

- Class I:** Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective.
- Class II:** Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.
- IIa:** Weight of evidence/opinion is in favor of usefulness/efficacy.
- IIb:** Usefulness/efficacy is less well established by evidence/opinion.
- Class III:** Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective and in some cases may be harmful.

The weight of the evidence was ranked highest (A) if the data were derived from multiple randomized clinical trials that involved large numbers of patients and intermediate (B) if the data were derived from a limited number of randomized trials that involved small numbers of patients or from careful analyses of nonrandomized studies or observational registries. A lower rank (C) was given when expert consensus was the primary basis for the recommendation.

## RISK ASSESSMENT

### Clinical Features

Unstable angina and NSTEMI are heterogeneous disorders in which patients have widely varying risks. Risk is an important "driver" of management decisions, and accurate yet simple methods of risk assessment are important for patient care.

Risk was assessed by multivariable regression techniques in patients presenting with UA/NSTEMI in several large clinical trials. Boersma et al. analyzed the relation between baseline characteristics and the incidence of death and the composite of death or myocardial (re)infarction at 30 days in patients who entered the PURSUIT (Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy) trial (2). The most important baseline features associated with death were age, heart rate, systolic blood pressure, ST-segment depression, signs of heart failure, and

elevation of cardiac biomarkers. From this analysis, a simple risk estimation score was developed.

Antman et al. developed a 7-point risk score, the "TIMI Risk Score," (age greater than or equal to 65 years, more than 3 coronary risk factors, prior angiographic coronary obstruction, ST-segment deviation, more than 2 angina events within 24 h, use of aspirin [ASA] within 7 days, and elevated cardiac markers) (3). The score was defined as the simple sum of these individual prognostic variables. The risk of developing an adverse outcome—death, (re)infarction, or recurrent severe ischemia that required revascularization—ranged from 5% with a score of 0 or 1 to 41% with a score of 6 or 7. The score was derived from data in the TIMI 11B (Thrombolysis In Myocardial Infarction 11B) trial (4) and then validated in 3 additional trials—ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events study) (5), and PRISM-PLUS (Platelet Receptor inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms) (6) and prospectively in one TACTICS-TIMI 18 (Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy—Thrombolysis In Myocardial Infarction) 18 (7). A progressively greater benefit from newer therapies such as low-molecular-weight heparin (LMWH) (4,5), platelet glycoprotein (GP) IIb/IIIa receptor antagonists (6), and an invasive strategy (7) with increasing risk score have been reported.

### Biomarkers

The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction (8) emphasized the use of troponins as critical markers of the presence of myocardial necrosis. Although troponins are accurate in identifying myocardial necrosis, the latter is not always secondary to atherosclerotic coronary artery disease. Therefore, in establishing the diagnosis of NSTEMI, cardiac troponins should be used in conjunction with appropriate clinical features and electrocardiographic changes. Myocardial injury of diverse origins (e.g., myocarditis, trauma, or cardioversion) may cause necrosis and release of troponins. Although these may be considered instances of NSTEMI, they should be distinguished on clinical grounds from the more common form of NSTEMI secondary to coronary atherosclerosis.

### Antiplatelet Therapy

Antiplatelet therapy is a cornerstone in the management of UA/NSTEMI. Three classes of antiplatelet drugs (ASA, thienopyridines, and GP IIb/IIIa antagonists) have been found useful in the management of these patients and are the subject of continued intensive investigation and analysis. Clopidogrel. Given its more rapid onset of action (9,10) and better safety profile compared with ticlopidine, clopidogrel is now the preferred thienopyridine. The CURE (Clopidogrel in Unstable angina to prevent Recurrent ischemic Events) trial (11) randomized 12,562 patients with

UA/NSTEMI who presented within 24 h to placebo or clopidogrel (loading dose of 300 mg followed by 75 mg daily) and followed them for 3 to 12 months; all patients were given aspirin. Cardiovascular death, myocardial infarction (MI), or stroke occurred in 11.5% of patients assigned to placebo and 9.3% of those assigned to clopidogrel (relative risk [RR] 0.80;  $p$  less than 0.001). Looking at the individual components of the primary composite and end point, there was a trend in favor of clopidogrel for cardiovascular death and stroke (5.5% and 1.4%, respectively, for placebo vs. 5.1% and 1.2% for clopidogrel), and there was a significant reduction in MI (6.7% vs. 5.2% R.R. = 0.77,  $p$  less than 0.001). However, there was no significant difference in the incidence of non-Q-wave MI (3.8% vs. 3.5%). A reduction in recurrent ischemia was noted within the first few hours after randomization. These salutary results were observed across all subgroups of patients. There was, however, a significant excess of major bleeding (2.7% in the placebo group versus 3.7% in the clopidogrel group;  $p$  = 0.003) and of minor bleeding, as well as a (nonsignificant) trend for an increase in life-threatening bleeding. The risk of bleeding was increased in patients who underwent coronary artery bypass grafting (CABG) within the first 5 days after clopidogrel was discontinued.

The CURE trial was performed in hospitals in which there was *no* routine policy of early invasive procedures, and therefore, revascularization was performed during the initial admission in only 23% of the patients, a substantially lower percentage than currently receive this therapy at most US hospitals. Although the addition of a GP IIb/IIIa antagonist appeared to be well tolerated in patients who were given ASA, clopidogrel, and heparin in CURE, fewer than 10% of patients received this combination. Therefore, additional information on the safety of "quadruple therapy" (heparin [unfractionated or low molecular weight], ASA, clopidogrel, and a GP IIb/IIIa antagonist) should be obtained.

The CURE trial provides strong support for the addition of clopidogrel to ASA on admission in the management of patients with UA and NSTEMI. Clopidogrel appears to be especially useful in hospitals that do not have a routine policy of early invasive procedures and in patients who are not candidates or who do not wish to be considered for revascularization. The optimal duration of therapy with clopidogrel has not been determined. The major benefits in CURE were observed at 30 days, with small additional benefits observed over the subsequent treatment period, which averaged 8 months.

In PCI-CURE, a substudy of CURE, 2,658 patients who underwent percutaneous coronary intervention (PCI) had been randomly assigned to double-blind treatment with clopidogrel ( $n$  = 1,313) or placebo ( $n$  = 1,345) (12); all patients also received ASA. Patients were pretreated with placebo or study drug for a median of 10 days before PCI. After the procedure, most patients received open-label thienopyridine (clopidogrel or ticlopidine) for approximately 4 weeks, after which the study drug (placebo or

clopidogrel) was again administered for an average of 8 months. The primary end point, a composite of cardiovascular death, MI, or urgent target-vessel revascularization within 30 days of PCI, occurred in 86 patients (6.4%) in the placebo group compared with 59 (4.5%) in the clopidogrel group (RR 0.70;  $p$  = 0.03). When events that occurred before and after PCI were considered, there was a 31% reduction in cardiovascular death or MI with assignment to clopidogrel ( $p$  = 0.002). Thus, in patients with UA and NSTEMI who are given ASA and are undergoing PCI, a strategy of clopidogrel pretreatment followed by at least 1 month and probably longer-term therapy is beneficial in reducing major cardiovascular events (12).

There now appears to be an important role for clopidogrel in patients with UA/NSTEMI, both those who are managed conservatively and those who undergo PCI, especially stenting. However, it is not entirely clear how long therapy should be maintained. Because clopidogrel, when added to ASA, increases the risk of bleeding during major surgery in patients who are scheduled for CABG, if possible, clopidogrel should be withheld for at least 5 days (11) and preferably for 7 days before surgery (13). In many hospitals in which patients with UA/NSTEMI undergo diagnostic catheterization within 24 to 36 h of admission, clopidogrel is not started until it is clear that CABG will *not* be scheduled within the next several days. A loading dose of clopidogrel can be given to a patient on the catheterization table if a PCI is to be performed immediately. If PCI is not performed, clopidogrel can be begun after the catheterization.

**Glycoprotein IIb/IIIa antagonists in PCI.** The introduction of platelet GP IIb/IIIa antagonists represents an important advance in the treatment of patients with UA/NSTEMI who are undergoing PCI. These drugs take advantage of the fact that platelets play an important role in the development of ischemic complications that may occur in patients with UA/NSTEMI during coronary revascularization procedures. The September 2000 guidelines emphasized the value of GP IIb/IIIa antagonists in patients with UA/NSTEMI who were undergoing PCI (1).

Two trials of GP IIb/IIIa inhibitors have been published since September 2000. The ESPRIT trial (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy) was a placebo-controlled trial designed to assess whether eptifibatid improved outcome in patients undergoing stenting (14). Fourteen percent of the 2,064 patients enrolled in ESPRIT had UA/NSTEMI. The primary end point (the composite of death, MI, target-vessel revascularization, and "bailout" GP IIb/IIIa antagonist therapy) was reduced from 10.5% to 6.6% with treatment ( $p$  = 0.0015). There was consistency in the reduction of events in all components of the end point and in all major subgroups, including patients with UA/NSTEMI. Major bleeding occurred more frequently in patients who received eptifibatid (1.3%) than in those who received placebo (0.4%;  $p$  = 0.027); however, no significant difference in the

transfusion rate occurred. At 1 year of follow-up, death or MI occurred in 12.4% of patients assigned to placebo and 8.0% of eptifibatide-treated patients (hazard ratio 0.63; 95% confidence interval [CI] 0.48 to 0.83;  $p = 0.001$ ) (15).

In the only head-to-head comparison of GP IIb/IIIa antagonists, the TARGET trial (Do Tirofiban and ReoPro Give similar Efficacy? Trial) randomized 5,308 patients to tirofiban or abciximab before PCI with the intent to perform stenting (16). The primary end point, a composite of death, nonfatal MI, and urgent target-vessel revascularization at 30 days, occurred less frequently in those given abciximab than in those given tirofiban (6.0% vs. 7.6%;  $p = 0.038$ ). There was a similar direction and magnitude for each component of the end point. The difference in outcome between the 2 treatment groups may be related to a suboptimal dose of tirofiban resulting in inadequate platelet inhibition. However, by six months, the primary end point occurred in a similar percentage of patients in each group (14.9% tirofiban vs. 14.3% abciximab, NS). Mortality was also similar (1.9% vs. 1.7%, NS) (17).

**Glycoprotein IIb/IIIa antagonists without scheduled PCI.** The Global Utilization of Strategies to Open Occluded Coronary Arteries IV-Acute Coronary Syndromes (GUSTO IV-ACS) trial (18) enrolled 7,800 patients with UA/NSTEMI who were admitted to the hospital with more than 5 min of chest pain and ST-segment depression and/or elevated troponin T or I concentration and in whom early (less than 48 h) revascularization was not intended to be conducted. All received ASA and either unfractionated heparin (UFH) or LMWH. They were randomized to placebo, an abciximab bolus and 24-h infusion, or an abciximab bolus and 48-h infusion. The primary end point, death or MI at 30 days, occurred in 8.0% of patients given placebo, 8.2% given 24-h abciximab, and 9.1% given 48-h abciximab, differences that were not statistically significant. At 48 h, death occurred in 0.3%, 0.7%, and 0.9% in these groups, respectively (placebo vs. abciximab 48 h,  $p = 0.008$ ). The lack of benefit of abciximab was observed in most subgroups, including patients with elevated concentrations of troponin who were at higher risk. Although the explanation for these results is not clear, they indicate that abciximab, at least at the dosing regimen used in GUSTO IV-ACS, is *not* indicated in the management of patients with UA or NSTEMI in whom an early invasive management strategy is not planned.

In the PRISM-PLUS trial, 1,069 patients did not undergo early PCI. Although tirofiban treatment was associated with a lower incidence of death, MI or death, and MI or refractory ischemia at 30 days, these reductions were not statistically significant (19). In a high-risk subgroup of these patients not undergoing PCI (TIMI risk score greater than or equal to 4) (3), tirofiban appeared to be beneficial whether they underwent PCI (odds ratio [OR] 0.60, 95% CI 0.35 to 1.01) or not (OR 0.69, 95% CI 0.49 to 0.99). However, no benefit was observed in the patients at lower risk (6). In the PURSUIT trial, eptifibatide reduced the

incidence of death or MI from 15.7% to 14.2% (RR 0.91; 95% CI 0.79 to 1.00;  $p = 0.032$ ) (20).

Boersma et al performed a meta-analysis of GP IIb/IIIa antagonists in all 6 large, randomized, placebo-controlled trials, including GUSTO IV-ACS (18), which involved 31,402 patients with UA/NSTEMI who were not routinely scheduled to undergo coronary revascularization (21). A small reduction in the odds of death or MI in the active treatment arm (11.8% vs 10.8%; OR 0.91, 95% CI 0.84 to 0.98;  $p = 0.015$ ) was observed. Unexpectedly, no benefit was observed in women (test for interaction between treatment assignment and gender,  $p$  less than 0.0001). However, women with positive troponins derived a treatment benefit that was similar to men. In the meta-analysis, reductions in the end points of death or nonfatal MI considered individually did *not* achieve statistical significance.

Although not scheduled for coronary revascularization procedures, 11,965 of the 31,402 patients (38%) actually underwent PCI or CABG within 30 days, and in this subgroup, the OR for death or MI in patients assigned to GP IIb/IIIa antagonists was 0.89 (95% CI 0.80 to 0.98). In the other 19,416 patients who did not undergo coronary revascularization, the OR for death or MI in the GP IIb/IIIa group was 0.95 (95% CI 0.86 to 1.05,  $p = NS$ ). Major bleeding complications were increased in the GP IIb/IIIa antagonist-treated group compared with those who received placebo (1.4% vs. 2.4%,  $p$  less than 0.0001). The authors concluded that in patients with UA/NSTEMI who were not routinely scheduled for early revascularization and who were at high risk of thrombotic complications, "treatment with a GP IIb/IIIa inhibitor might therefore be considered" (21). Thus, GP IIb/IIIa inhibitors are of benefit in high-risk patients with UA/NSTEMI, and their administration, in addition to ASA and heparin, to patients in whom catheterization and PCI are planned received a Class I recommendation. These agents are of questionable benefit in patients who do not undergo PCI. However, the revised guidelines recommend broader indications for a routine invasive strategy (see following text).

Thus, clopidogrel (in addition to aspirin and heparin or low molecular weight heparin) is recommended for patients with UA/NSTEMI in whom a noninterventional approach is planned (Class I recommendation). In patients in whom an interventional approach is planned, a GP IIb/IIIa inhibitor (in addition to aspirin and heparin or low molecular weight heparin) is recommended (Class I recommendation). No head-to-head comparison of clopidogrel, a GP IIb/IIIa inhibitor, and their combination has been reported. The addition of a GP IIb/IIIa inhibitor to a subset of patients in the CURE trial who were receiving aspirin, clopidogrel, and heparin appeared to be well tolerated, and current practice frequently involves the use of this combination of drugs. However, until further information on the safety and efficacy of such quadruple therapy becomes available, a Class IIa recommendation is made for the addition of a GP IIb/IIIa inhibitor for patients with UA/NSTEMI who are

receiving aspirin, clopidogrel, and unfractionated or low molecular weight heparin and who are referred for an invasive strategy. A Class I recommendation is made for a GP IIb/IIIa inhibitor at the time of PCI in patients receiving heparin and aspirin. Specific updated recommendations for the use of antiplatelet regimens in the revised guidelines are as follows:

#### Class I

1. Antiplatelet therapy should be initiated promptly. ASA should be administered as soon as possible after presentation and continued indefinitely. (Level of Evidence: A)
2. Clopidogrel should be administered to hospitalized patients who are unable to take ASA because of hypersensitivity or major gastrointestinal intolerance. (Level of Evidence: A)
- \*3. In hospitalized patients in whom an early noninterventional approach is planned, clopidogrel should be added to ASA as soon as possible on admission and administered for at least 1 month (Level of Evidence: A), and for up to 9 months. (Level of Evidence: B)
- \*4. A platelet GP IIb/IIIa antagonist should be administered, in addition to ASA and heparin, to patients in whom catheterization and PCI are planned. The GP IIb/IIIa antagonist may also be administered just prior to PCI. (Level of Evidence: A)
- \*5. In patients for whom a PCI is planned and who are not at high risk for bleeding, clopidogrel should be started and continued for at least 1 month (Level of Evidence: A) and for up to 9 months. (Level of Evidence: B)
- \*6. In patients taking clopidogrel in whom elective CABG is planned, the drug should be withheld for 5 to 7 days. (Level of Evidence: B)

#### Class IIa

- \*1. Eptifibatid or tirofiban should be administered, in addition to ASA and LMWH or UFH, to patients with continuing ischemia, an elevated troponin, or with other high-risk features in whom an invasive management strategy is not planned. (Level of Evidence: A)
- \*2. A platelet GP IIb/IIIa antagonist should be administered to patients already receiving heparin, ASA, and clopidogrel in whom catheterization and PCI are planned. The GP IIb/IIIa antagonist may also be administered just prior to PCI. (Level of Evidence: B)

#### Class IIb

- \*1. Eptifibatid or tirofiban, in addition to ASA and LMWH or UFH, to patients without continuing

ischemia who have no other high-risk features and in whom PCI is not planned. (Level of Evidence: A)

#### Class III

1. Intravenous fibrinolytic therapy in patients without acute ST-segment elevation, a true posterior MI, or a presumed new left bundle-branch block. (Level of Evidence: A)
- \*2. Abciximab administration in patients in whom PCI is not planned. (Level of Evidence: A)

\*New indication, not included in the September 2000 guidelines.

†Minor clarification different from full-text version on web site.

#### Anticoagulant Therapy

The September 2000 guidelines (1) reviewed the evidence regarding the use of intravenous UFH or subcutaneous LMWH. It provided the following Class I recommendation:

"Parenteral anticoagulation with intravenous UFH or subcutaneous LMWH should be added to antiplatelet therapy with ASA or a thienopyridine. (Level of Evidence: B)"

In the interim, a number of studies have appeared that support the use of enoxaparin. In the EVET trial (Enoxaparin Versus Tinzaparin in the management of unstable coronary artery disease), 2 LMWHs, enoxaparin and tinzaparin, administered for 7 days, were compared in 438 patients with UA/NSTEMI. A preliminary report stated that both the recurrence of unstable angina and the need for revascularization were significantly lower in the enoxaparin group (22). Because the level of anticoagulant activity cannot be easily measured in patients given LMWH (e.g., activated partial thromboplastin time or activated clotting time), interventional cardiologists have expressed concern about the substitution of LMWH for UFH in patients scheduled for catheterization with possible PCI. However, Collet et al. (23) have shown in a small nonrandomized observation study in 293 patients that PCI can be performed safely with UA/NSTEMI patients who received the usual dose of enoxaparin. In NICE-1 (National Investigators Collaborating on Enoxaparin), an observational study, intravenous enoxaparin (1.0 mg/kg) was used in 828 patients undergoing elective PCI without an intravenous GP IIb/IIIa antagonist (24). The rates of bleeding (1.1% major bleeding and 6.2% minor bleeding in 30 days) were comparable to those observed in historical controls with UFH.

An alternative approach is to use LMWH during the period of initial stabilization and to withhold the dose on the morning of the procedure. If an intervention is required and more than 8 h has elapsed since the last dose of LMWH, UFH can be used for PCI according to usual practice patterns. Because the anticoagulant effect of UFH can be more readily reversed than that of LMWH, UFH is preferred in patients likely to undergo CABG within 24 h.

The September 2000 guidelines reflected concern regarding the combined use of LMWH and GP IIb/IIIa antagonists. Although the data are not definitive, it now appears that GP IIb/IIIa antagonists can be used with LMWH. In the ACUTE II (Anti-thrombotic Combination Using Tirofiban and Enoxaparin II) study (25), UFH and enoxaparin were compared in patients with UA/NSTEMI who were given tirofiban. The frequencies of both major and minor bleeding were similar, and there was a trend to fewer adverse events in the patients given enoxaparin. A number of other open-label studies have examined the safety of combining enoxaparin with abciximab, eptifibatide, or tirofiban in patients with UA/NSTEMI who are treated with PCI or conservatively; of combining enoxaparin with abciximab in patients undergoing elective PCI (26); and of combining dalteparin with abciximab in patients with UA/NSTEMI who are treated conservatively and during PCI (27). Although the majority of these studies relied on historical controls, none suggested that the combination of enoxaparin and a GP IIb/IIIa antagonist was associated with excess bleeding, whether or not the patient also underwent PCI.

Specific recommendations for the use of heparins in the revised guidelines are as follows:

#### Class I

1. Anticoagulation with subcutaneous LMWH or intravenous UFH should be added to antiplatelet therapy with ASA and/or clopidogrel. (*Level of Evidence: A*)

#### Class IIa

- †1. Enoxaparin is preferable to UFH as an anticoagulant in patients with UA/NSTEMI, in the absence of renal failure and unless CABG is planned within 24 h. (*Level of Evidence: A*)

\*New indication, not included in the September 2000 guidelines.

†Minor clarification different from full-text version on web site.

### EARLY CONSERVATIVE VS. EARLY INVASIVE STRATEGIES

The September 2000 guidelines indicated that 2 different treatment strategies, termed "early conservative" and "early invasive," may be used in patients with UA/NSTEMI (1). In the early conservative strategy, coronary angiography is reserved for patients with evidence of recurrent ischemia (angina at rest or with minimal activity or dynamic ST-segment changes) or a strongly positive stress test despite vigorous medical therapy. In the *early invasive strategy*, patients without clinically obvious contraindications to coronary revascularization are routinely recommended for coronary angiography and angiographically directed revascularization, if possible.

Several trials comparing these 2 strategies were reviewed,

but greatest attention was paid to the then-most-recent trial, FRISC II (Fragmin and Fast Revascularization during InStability in Coronary artery disease II) (28). At 1 year, the mortality rate in the invasive strategy group was 2.2% compared with 3.9% in the noninvasive strategy group ( $p = 0.016$ ) (29). However, in FRISC II, the invasive strategy involved treatment for an average of 6 days in the hospital with LMWH, ASA, nitrates, and beta-blockers before coronary angiography, an approach that would be difficult to adopt in U.S. hospitals.

In the interim, the TACTICS-TIMI 18 trial was reported (7). In this trial, 2,220 patients with UA or NSTEMI were treated with ASA, heparin, and the GP IIb/IIIa antagonist tirofiban. They were then randomized to an early invasive strategy with routine coronary angiography within 48 h followed by revascularization if the coronary anatomy was deemed suitable, or to a more conservative strategy. In the latter, catheterization was performed only if the patient had recurrent ischemia or a strongly positive stress test. Death, myocardial (re)infarction, or rehospitalization for an acute coronary syndrome at 6 months occurred in 19.4% of patients assigned to the conservative strategy vs. 15.9% assigned to the invasive strategy (OR 0.78; 95% CI 0.62 to 0.97;  $p = 0.025$ ). Occurrence of death or MI was also reduced at 6 months (9.5% vs 7.3%;  $p$  less than 0.05). The beneficial effects on outcome were particularly evident in medium- and high-risk patients, as defined by an elevation of troponin T greater than 0.01 ng/ml or of troponin I greater than 0.1 ng/ml, the presence of ST-segment deviation, or a TIMI risk score greater than or equal to 3 (7,30). In the absence of these high-risk features, outcomes in patients assigned to the 2 strategies were similar. Rates of major bleeding were similar, and lengths of hospital stay were reduced in patients assigned to the invasive strategy. The benefits of the invasive strategy were achieved at no significant increase in the cost of care over the 6-month follow-up period.

Thus, both the FRISC II (28,29) and TACTICS-TIMI 18 (7,30) trials, the 2 most recent trials comparing invasive vs. conservative strategies in patients with UA/NSTEMI, showed a benefit in patients assigned to the invasive strategy. In contrast to earlier trials, a large majority of patients undergoing PCI in these 2 trials received coronary stents as opposed to balloon angioplasty alone. In TACTICS-TIMI 18, treatment included the GP IIb/IIIa antagonist tirofiban, which was administered for an average of 22 h before coronary angiography. The routine use of the GP IIb/IIIa antagonist in this trial may have eliminated the excess risk of early (within 7 days) acute MI in the invasive arm, an excess risk that was observed in FRISC II and other trials in which there was no routine "upstream" use of a GP IIb/IIIa antagonist. Therefore, an invasive strategy is associated with a better outcome in UA/NSTEMI patients at high risk who receive a GP IIb/IIIa antagonist (7). Although the benefit of GP IIb/IIIa antagonists is well established for patients with UA/NSTEMI who undergo PCI, the optimum

time of commencing these drugs—as early as possible after presentation, i.e. “upstream,” as in TACTICS-TIMI 18, or just before the PCI—has not been established.

Specific recommendations for the use of an invasive strategy in the revised guidelines are as follows:

#### Class I

- †1. An early invasive strategy in patients with UA/NSTEMI without serious comorbidity and who have any of the following high-risk indicators: (*Level of Evidence: A*)
  - \*a) Recurrent angina/ischemia at rest or with low-level activities despite intensive anti-ischemic therapy.
  - \*b) Elevated TnT or TnI
  - \*c) New or presumably new ST-segment depression
  - d) Recurrent angina/ischemia with CHF symptoms, an S<sub>3</sub> gallop, pulmonary edema, worsening rales, or new or worsening MR
  - e) High-risk findings on noninvasive stress testing
  - f) Depressed LV systolic function (e.g., EF less than 0.40 on noninvasive study)
  - g) Hemodynamic instability
  - h) Sustained ventricular tachycardia
  - i) PCI within 6 months
  - j) Prior CABG
2. In the absence of any of these findings, either an early conservative or an early invasive strategy may be offered in hospitalized patients without contraindications for revascularization. (*Level of Evidence: B*)

\*New indication, not included in the September 2000 guidelines.

†Minor clarification different from full-text version on web site.

#### RISK FACTOR MODIFICATION

The September 2000 guidelines pointed out that despite the overwhelming evidence for the benefits of beta-hydroxy-beta-methylglutaryl-coenzyme A (HMG-CoA) reductase (statin) therapy in patients with elevated low-density lipoprotein (LDL) cholesterol levels, almost no data existed about the timing of initiation of therapy in patients with acute coronary syndromes (1). Indeed, the secondary prevention trials of statins specifically excluded patients with UA/NSTEMI in the acute phase. Fewer than 300 patients had been entered into the trials within 4 months of an acute coronary syndrome.

The Lipid-Coronary Artery Disease (L-CAD) study was a small trial that randomized 126 patients with an acute coronary syndrome to early treatment with pravastatin, alone or in combination with cholestyramine or niacin, or to usual care. At 24 months, the patients who received early aggressive treatment had a lower incidence of clinical events

(23%) than the usual-care group (52%;  $p = 0.005$ ) (31). In the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) trial, 3,086 patients were randomized to treatment with an aggressive lipid-lowering regimen of atorvastatin 80 mg per day or placebo 24 to 96 h after an acute coronary syndrome (32). At 16 weeks of follow-up, the primary end point of death, nonfatal MI, resuscitated cardiac arrest, or recurrent severe myocardial ischemia was reduced from 17.4% in the placebo group to 14.8% in the atorvastatin group ( $p = 0.048$ ). There were no significant differences between the 2 groups in the risk of the following individual end points: death, nonfatal MI, cardiac arrest, or worsening heart failure; however, there were fewer strokes and a lower risk of severe recurrent ischemia in patients assigned to atorvastatin.

Although the evidence from these 2 trials of a beneficial effect of pre-discharge initiation of lipid-lowering therapy is not yet robust or definitive, observational studies support this policy. In the Swedish Registry of Cardiac Intensive Care of almost 20,000 patients, the adjusted relative risk of mortality was 25% lower in patients in whom statin therapy was initiated before hospital discharge (33). In addition, patients in whom lipid-lowering therapy is begun in the hospital are much more likely to be undergoing such therapy at a later time. In one demonstration project, the Cardiovascular Hospitalization Atherosclerosis Management Program (CHAMP), the in-hospital initiation of lipid-lowering therapy was associated with an increased percentage of patients treated with statins 1 year later (from 10% to 91%) and with a higher frequency of patients whose LDL cholesterol was less than 100 mg/dl (from 6% to 58%) (34). Although additional trials are ongoing, there appear to be no adverse effects and substantial advantages to the initiation of lipid-lowering therapy before hospital discharge (35–37). Such early initiation of therapy has also been recommended in the third report of the National Cholesterol Education Program (NCEP III), which also raised the threshold of high-density lipoprotein cholesterol concentration that required therapy (38). Similar considerations apply to the early initiation of statin therapy following PCI. In the Lescol Intervention Prevention Study (LIPS), 1,669 patients were randomized to receive 80 mg fluvastatin or placebo, beginning two days after PCI. After a follow-up of 3.9 years, the statin-treated group had a lower incidence of clinical events (21.4%) than the placebo group (26.7%),  $p = 0.01$  (39).

In addition to maintaining the original Class I recommendations for LDL cholesterol reduction, specific additional recommendations for the use of lipid-lowering therapy in UA/NSTEMI in the revised guidelines are as follows:

#### Class I

- \*1. A fibrate or niacin if high-density lipoprotein cholesterol is less than 40 mg per dl, occurring as

an isolated finding or in combination with other lipid abnormalities. (Level of Evidence: B)

#### Class IIa

1. HMG-CoA reductase inhibitors and diet for LDL cholesterol greater than 100 mg per dl begun 24 to 96 h after admission and continued at hospital discharge. (Level of Evidence: B)

\*New indication, not included in the September 2000 guidelines.

#### CONCLUSIONS

These guidelines address the diagnosis and management of patients with UA and the closely related condition NSTEMI. These life-threatening disorders are a major cause of emergency medical care and are responsible for more than 1.4 million hospitalizations annually in the United States (40). Nearly 60% of these admissions are among persons greater than 65 years old, and almost half occur in women. In 1997, there were 5,315,000 visits to US emergency departments for the evaluation of chest pain and related symptoms (41).

Because of the high incidence of UA/NSTEMI and the seriousness of this condition (approximately 15% rate of death or [re]infarction at 30 days) (1,20), continued research in this field is of the greatest importance. It is encouraging that in the 21 months since the publication of the September 2000 guidelines, a considerable body of additional useful information about these conditions has emerged. Indeed, the progress between September 2000 and June 2002 equals that between 1994, when the first guidelines were published (42), and September 2000.

#### REFERENCES

1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). *J Am Coll Cardiol* 2000;36:970-1062.
2. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. The PURSUIT Investigators. *Circulation* 2000;101:2557-67.
3. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. *JAMA* 2000;284:835-42.
4. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. *Circulation* 1999;100:1593-601.
5. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. *N Engl J Med* 1997;337:447-52.
6. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. *Eur Heart J* 2002;23:223-9.
7. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med* 2001;344:1879-87.
8. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the re-definition of myocardial infarction. *J Am Coll Cardiol* 2000;36:959-69.
9. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. *Circulation* 2000;101:2823-8.
10. Helft G, Osende JJ, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. *Arterioscler Thromb Vasc Biol* 2000;20:2316-21.
11. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494-502.
12. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001;358:527-33.
13. Physicians' desk reference. 56 ed. Montvale, NJ: Medical Economics Company, Inc., 2002:3085.
14. The ESPRIT Investigators. Novel dosing regimen of eptifibatid in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. *Lancet* 2000;356:2037-44.
15. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatid in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. *JAMA* 2001;285:2468-73.
16. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. *N Engl J Med* 2001;344:1888-94.
17. Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. *Circulation* 2002;105:2730-6.
18. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. *Lancet* 2001;357:1915-24.
19. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study investigators. *N Engl J Med* 1998;338:1488-97.
20. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatid in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. *N Engl J Med* 1998;339:436-43.
21. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. *Lancet* 2002;359:189-98.
22. Michalis LK, Papanichail N, Katsouras C. Enoxaparin Versus Tirofiban in the Management of Unstable Coronary Artery Disease (EVET Study) (abstr). *J Am Coll Cardiol* 2001;37 Suppl:365a.
23. Collet JP, Montalecot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. *Circulation* 2001;103:658-63.
24. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. *J Invasive Cardiol* 2001;13:272-8.
25. Cohen M, Theroux P, White HD. Anti-Thrombotic Combination Using Tirofiban and Enoxaparin: The ACUTE II Study (abstr). *Circulation* 2000;102:II826.
26. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. *J Invasive Cardiol* 2000;12 Suppl E:E14-8.

27. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. *Am Heart J* 2001;141:348-52.
28. The FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. *Lancet* 1999;354:708-15.
29. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. *Fast Revascularisation during Instability in Coronary artery disease. Lancet* 2000;356:9-16.
30. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. *JAMA* 2001;286:2405-12.
31. Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). *Am J Cardiol* 2000;86:1293-8.
32. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. a randomized controlled trial. *JAMA* 2001;285:1711-8.
33. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. *JAMA* 2001;285:430-6.
34. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). *Am J Cardiol* 2001;87:819-22.
35. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. *Am J Cardiol* 2001;87:257-61.
36. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. *Circulation* 2001;103:2768-70.
37. Michels KB, Braunwald E. Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials. *JAMA* 2002;287:3130-2.
38. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-97.
39. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002;287:3215-22.
40. National Center for Health Statistics. Detailed diagnoses and procedures: National Hospital Discharge Survey, 1996. Hyattsville, MD: National Center for Health Statistics; 1998:13. Data from Vital and Health Statistics.
41. Nourjah P. National Hospital Ambulatory Medical Care Survey: 1997 emergency department summary. Hyattsville, MD: National Center for Health Statistics; 1999:304. Advance data from Vital and Health Statistics.
42. Braunwald E, Mark DB, Jones RH, et al. Unstable Angina: Diagnosis and Management. AHCPR Publication No 94-0602, 1-154. 3-1-1994. Rockville, MD, Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, U.S. Department of Health and Human Services.